ArticleResearch square2024
CCR5 Decorated Rilpivirine Lipid Nanoparticles Build Myeloid Drug Depots Which Sustains Antiretroviral Activities.
Howard E Gendelman, Milankumar Patel, Sudipta Panja, Lubaba A Zaman, Pravin Yeapuri, Shaurav Bhattarai, Santhi Gorantla, Linda Chang, Alonso Heredia, Piotr Walczak and 2 more
Abstract readPreprint
In one paragraphArticle in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
12 authors.
Milankumar PatelUniversity of Nebraska Medical Center.
Sudipta PanjaUniversity of Nebraska Medical Center.
Lubaba A ZamanUniversity of Nebraska Medical Center.
Pravin YeapuriUniversity of Nebraska Medical Center.
Shaurav BhattaraiUniversity of Nebraska Medical Center.
Santhi GorantlaUniversity of Nebraska Medical Center.
Alonso HerediaUniversity of Maryland.
Samuel CohenDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.ORCID 0000-0002-5047-0962 Bhavesh KevadiyaUniversity of Nebraska Medical Center.
Funding
Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2000 to 2021
$37.7MTargeted Neuro Protection of HIV-1 Associated Neurologic DiseaseP01MH064570 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2001 to 2014
$19.4MPharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ALNOUTI, YAZEN · 2010 to 2019
$16.8MNeuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3MNanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7MTargeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirsR01MH121402 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$4.9MCombined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5MLASER ART for PrePR01AI158160 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI EDAGWA, BENSON, GENDELMAN, HOWARD E · 2021 to 2025
$3.5MHIV-1DetectionandEliminationFrom CNS Mononuclear PhagocytesR01NS126089 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, GORANTLA, SANTHI · 2021 to 2025
$3.5MImpact of drugs of abuse on HIV brain reservoirs and HAND in humanized microglia miceR01DA054535 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GORANTLA, SANTHI · 2021 to 2025
$2.7MNIAID NIH HHS R01 AI158160NIDA NIH HHS P01 DA028555NIDA NIH HHS R01 DA054535NIMH NIH HHS P01 MH064570NIMH NIH HHS P30 MH062261NIMH NIH HHS R01 MH115860NIMH NIH HHS R01 MH121402NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS R01 NS126089
6 · The paper itselfAbstract
Antiretroviral therapy (ART) improves the quality of life for those living with the human immunodeficiency virus type one (HIV-1). However, poor compliance reduces ART effectiveness and leads to immune compromise, viral mutations, and disease co-morbidities. A novel drug formulation is made whereby a lipid nanoparticle (LNP) carrying rilpivirine (RPV) is decorated with the C-C chemokine receptor type 5 (CCR5). This facilitates myeloid drug depot deposition. Particle delivery to viral reservoirs is tracked by positron emission tomography. The CCR5-mediated RPV LNP cell uptake and retention reduce HIV-1 replication in human monocyte-derived macrophages and infected humanized mice. Focused ultrasound allows the decorated LNP to penetrate the blood-brain barrier and reach brain myeloid cells. These findings offer a role for CCR5-targeted therapeutics in antiretroviral delivery to optimize HIV suppression.
Indexed as
antiretroviral therapyCCR5-targetingHIVlipid nanoparticlesnon-invasive imaging
Identifiers
PMID38883780
PMCPMC11177988
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390